Therapeutic Targeting of the Tumor Microenvironment

Cancer Discov. 2021 Apr;11(4):933-959. doi: 10.1158/2159-8290.CD-20-1808.

Abstract

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a promising approach for cancer treatment in recent years due to the critical roles of the TME in regulating tumor progression and modulating response to standard-of-care therapies. Here, we summarize the current knowledge regarding the most advanced TME-directed therapies, which have either been clinically approved or are currently being evaluated in trials, including immunotherapies, antiangiogenic drugs, and treatments directed against cancer-associated fibroblasts and the extracellular matrix. We also discuss some of the challenges associated with TME therapies, and future perspectives in this evolving field. SIGNIFICANCE: This review provides a comprehensive analysis of the current therapies targeting the TME, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Cancer-Associated Fibroblasts
  • Extracellular Matrix
  • Humans
  • Immunotherapy / trends
  • Neoplasms / drug therapy*
  • Tumor Microenvironment*

Substances

  • Angiogenesis Inhibitors